» Articles » PMID: 35332154

The Potential Convergence of NLRP3 Inflammasome, Potassium, and Dopamine Mechanisms in Parkinson's Disease

Overview
Date 2022 Mar 25
PMID 35332154
Authors
Affiliations
Soon will be listed here.
Abstract

The pathology of Parkinson's disease (PD) is characterized by α-synuclein aggregation, microglia-mediated neuroinflammation, and dopaminergic neurodegeneration in the substantia nigra with collateral striatal dopamine signaling deficiency. Microglial NLRP3 inflammasome activation has been linked independently to each of these facets of PD pathology. The voltage-gated potassium channel Kv1.3, upregulated in microglia by α-synuclein and facilitating potassium efflux, has also been identified as a modulator of neuroinflammation and neurodegeneration in models of PD. Evidence increasingly suggests that microglial Kv1.3 is mechanistically coupled with NLRP3 inflammasome activation, which is contingent on potassium efflux. Potassium conductance also influences dopamine release from midbrain dopaminergic neurons. Dopamine, in turn, has been shown to inhibit NLRP3 inflammasome activation in microglia. In this review, we provide a literature framework for a hypothesis in which Kv1.3 activity-induced NLRP3 inflammasome activation, evoked by stimuli such as α-synuclein, could lead to microglia utilizing dopamine from adjacent dopaminergic neurons to counteract this process and fend off an activated state. If this is the case, a sufficient dopamine supply would ensure that microglia remain under control, but as dopamine is gradually siphoned from the neurons by microglial demand, NLRP3 inflammasome activation and Kv1.3 activity would progressively intensify to promote each of the three major facets of PD pathology: α-synuclein aggregation, microglia-mediated neuroinflammation, and dopaminergic neurodegeneration. Risk factors overlapping to varying degrees to render brain regions susceptible to such a mechanism would include a high density of microglia, an initially sufficient supply of dopamine, and poor insulation of the dopaminergic neurons by myelin.

Citing Articles

Changes of NLRP3 in serum and cerebrospinal fluid of patients after moderate to severe traumatic brain injury and their predictive values for prognosis.

Chen W, Wang Z, Ye G, Zhu G, Li S, Chen P CNS Neurosci Ther. 2024; 30(9):e70009.

PMID: 39302033 PMC: 11413909. DOI: 10.1111/cns.70009.


Alpha Synuclein Toxicity and Non-Motor Parkinson's.

Mazzotta G, Conte C Cells. 2024; 13(15.

PMID: 39120295 PMC: 11311369. DOI: 10.3390/cells13151265.


Association between serum potassium and Parkinson's disease in the US (NHANES 2005-2020).

Zhou X, Zhao J, Liu Y, Sun X, Li X, Ren J Front Neurosci. 2024; 18:1387266.

PMID: 38784091 PMC: 11111918. DOI: 10.3389/fnins.2024.1387266.


Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches.

Firdaus Z, Li X Int J Mol Sci. 2024; 25(4).

PMID: 38396996 PMC: 10889342. DOI: 10.3390/ijms25042320.


Design and Discovery of Novel NLRP3 Inhibitors and PET Imaging Radiotracers Based on a 1,2,3-Triazole-Bearing Scaffold.

Xu Y, Xu Y, Biby S, Kaur B, Liu Y, Bagdasarian F J Med Chem. 2023; 67(1):555-571.

PMID: 38150705 PMC: 11002996. DOI: 10.1021/acs.jmedchem.3c01782.


References
1.
Glass C, Saijo K, Winner B, Marchetto M, Gage F . Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6):918-34. PMC: 2873093. DOI: 10.1016/j.cell.2010.02.016. View

2.
Paul K, Schulz J, Bronstein J, Lill C, Ritz B . Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease. JAMA Neurol. 2018; 75(3):360-366. PMC: 5885856. DOI: 10.1001/jamaneurol.2017.4206. View

3.
Jiang P, Dickson D . Parkinson's disease: experimental models and reality. Acta Neuropathol. 2017; 135(1):13-32. PMC: 5828522. DOI: 10.1007/s00401-017-1788-5. View

4.
Nussbaum R, Ellis C . Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003; 348(14):1356-64. DOI: 10.1056/NEJM2003ra020003. View

5.
Tran J, Anastacio H, Bardy C . Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells. NPJ Parkinsons Dis. 2020; 6:8. PMC: 7181694. DOI: 10.1038/s41531-020-0110-8. View